Free Trial
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

BioXcel Therapeutics logo
$2.12 -0.19 (-8.23%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$2.09 -0.03 (-1.42%)
As of 03/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

Key Stats

Today's Range
$2.09
$2.31
50-Day Range
$1.73
$6.08
52-Week Range
$1.72
$49.58
Volume
138,545 shs
Average Volume
1.16 million shs
Market Capitalization
$6.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.60
Consensus Rating
Moderate Buy

Company Overview

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Remove Ads

BioXcel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

BTAI MarketRank™: 

BioXcel Therapeutics scored higher than 93% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioXcel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    BioXcel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioXcel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($24.39) to ($16.32) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioXcel Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioXcel Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BioXcel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.08% of the float of BioXcel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BioXcel Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioXcel Therapeutics has recently decreased by 33.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioXcel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BioXcel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.08% of the float of BioXcel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BioXcel Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioXcel Therapeutics has recently decreased by 33.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioXcel Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for BioXcel Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    28 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.20% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 30.68% of the stock of BioXcel Therapeutics is held by institutions.

  • Read more about BioXcel Therapeutics' insider trading history.
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

BioXcel Therapeutics price target lowered to $1 from $4 at BofA
DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
See More Headlines

BTAI Stock Analysis - Frequently Asked Questions

BioXcel Therapeutics' stock was trading at $5.9824 at the start of the year. Since then, BTAI stock has decreased by 64.6% and is now trading at $2.12.
View the best growth stocks for 2025 here
.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings data on Thursday, March, 27th. The company reported ($3.57) EPS for the quarter, topping the consensus estimate of ($4.36) by $0.79. The company earned $0.30 million during the quarter, compared to the consensus estimate of $0.72 million.

Shares of BioXcel Therapeutics reverse split on the morning of Monday, February 10th 2025. The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional shareholders of BioXcel Therapeutics include Geode Capital Management LLC (0.63%), Wells Fargo & Company MN (0.40%), Millennium Management LLC (0.21%) and Renaissance Technologies LLC (0.16%). Insiders that own company stock include Vimal Mehta, Richard I Steinhart, Vincent O'neill, Matthew T Wiley, Frank Yocca and Krishnan Nandabalan.
View institutional ownership trends
.

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA).

Company Calendar

Last Earnings
3/27/2025
Today
3/31/2025
Next Earnings (Estimated)
4/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
90
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$42.60
High Stock Price Target
$80.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,909.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-179,050,000.00
Net Margins
-3,119.33%
Pretax Margin
-3,119.33%

Debt

Sales & Book Value

Annual Sales
$2.28 million
Price / Cash Flow
N/A
Book Value
($30.21) per share
Price / Book
-0.07

Miscellaneous

Free Float
2,444,000
Market Cap
$6.80 million
Optionable
Optionable
Beta
0.89

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:BTAI) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners